171 related articles for article (PubMed ID: 10853011)
1. Fas and Fas ligand interactions in malignant disease.
Owen-Schaub L; Chan H; Cusack JC; Roth J; Hill LL
Int J Oncol; 2000 Jul; 17(1):5-12. PubMed ID: 10853011
[TBL] [Abstract][Full Text] [Related]
2. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the Fas/FasL pathway in the pathogenesis of germ cell tumours of the adult testis.
Kersemaekers AM; van Weeren PC; Oosterhuis JW; Looijenga LH
J Pathol; 2002 Apr; 196(4):423-9. PubMed ID: 11920738
[TBL] [Abstract][Full Text] [Related]
4. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
[TBL] [Abstract][Full Text] [Related]
5. The breakdown of apoptotic mechanism in the development and progression of colorectal carcinoma.
Ogawa S; Nagao M; Kanehiro H; Hisanaga M; Ko S; Ikeda N; Nakajima Y
Anticancer Res; 2004; 24(3a):1569-79. PubMed ID: 15274324
[TBL] [Abstract][Full Text] [Related]
6. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.
Gopalan B; Litvak A; Sharma S; Mhashilkar AM; Chada S; Ramesh R
Cancer Res; 2005 Apr; 65(8):3017-24. PubMed ID: 15833826
[TBL] [Abstract][Full Text] [Related]
7. Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals.
Scholz M; Cinatl J
Med Res Rev; 2005 May; 25(3):331-42. PubMed ID: 15599929
[TBL] [Abstract][Full Text] [Related]
8. The Fas signalling pathway and its role in the pathogenesis of cancer.
Houston A; O'Connell J
Curr Opin Pharmacol; 2004 Aug; 4(4):321-6. PubMed ID: 15251123
[TBL] [Abstract][Full Text] [Related]
9. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
10. New kids in the block: the role of FasL and Fas in kidney damage.
Ortiz A; Lorz C; Egido J
J Nephrol; 1999; 12(3):150-8. PubMed ID: 10440512
[TBL] [Abstract][Full Text] [Related]
11. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.
Korkolopoulou P; Goudopoulou A; Voutsinas G; Thomas-Tsagli E; Kapralos P; Patsouris E; Saetta AA
Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989
[TBL] [Abstract][Full Text] [Related]
12. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.
Walker PR; Saas P; Dietrich PY
J Immunol; 1997 May; 158(10):4521-4. PubMed ID: 9144461
[TBL] [Abstract][Full Text] [Related]
13. The role of Fas and FasL as mediators of anticancer chemotherapy.
Poulaki V; Mitsiades CS; Mitsiades N
Drug Resist Updat; 2001 Aug; 4(4):233-42. PubMed ID: 11991678
[TBL] [Abstract][Full Text] [Related]
14. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.
Ragnarsson GB; Mikaelsdottir EK; Vidarsson H; Jónasson JG; Olafsdóttir K; Kristjánsdóttir K; Kjartansson J; Ogmundsdóttir HM; Rafnar T
Br J Cancer; 2000 Dec; 83(12):1715-21. PubMed ID: 11104571
[TBL] [Abstract][Full Text] [Related]
15. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
Shimizu M; Kondo M; Ito Y; Kume H; Suzuki R; Yamaki K
Cancer Detect Prev; 2005; 29(2):175-80. PubMed ID: 15829378
[TBL] [Abstract][Full Text] [Related]
16. FK506 restores sensitivity of thymic lymphomas to calcium-mediated apoptosis and the inducible expression of Fas ligand.
Kalas W; Matuszyk J; Ziolo E; Strzadala L
Anticancer Res; 2003; 23(2B):1613-7. PubMed ID: 12820430
[TBL] [Abstract][Full Text] [Related]
17. Expression level of c-FLIP versus Fas determines susceptibility to Fas ligand-induced cell death in murine thymoma EL-4 cells.
Kataoka T; Ito M; Budd RC; Tschopp J; Nagai K
Exp Cell Res; 2002 Feb; 273(2):256-64. PubMed ID: 11822881
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
Mitsiades N; Yu WH; Poulaki V; Tsokos M; Stamenkovic I
Cancer Res; 2001 Jan; 61(2):577-81. PubMed ID: 11212252
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
Huerta-Yepez S; Vega M; Garban H; Bonavida B
Clin Immunol; 2006 Sep; 120(3):297-309. PubMed ID: 16784892
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line.
Chang JS; Hsu YL; Kuo PL; Chiang LC; Lin CC
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):716-22. PubMed ID: 15554914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
